262 related articles for article (PubMed ID: 10855628)
1. Decreased serum E-selectin concentration after 89Sr-chloride therapy for metastatic prostate cancer bone pain.
Papatheofanis FJ
J Nucl Med; 2000 Jun; 41(6):1021-4. PubMed ID: 10855628
[TBL] [Abstract][Full Text] [Related]
2. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
Papatheofanis FJ
J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
[TBL] [Abstract][Full Text] [Related]
3. Bone pain palliation with 85Sr therapy.
Giammarile F; Mognetti T; Blondet C; Desuzinges C; Chauvot P
J Nucl Med; 1999 Apr; 40(4):585-90. PubMed ID: 10210217
[TBL] [Abstract][Full Text] [Related]
4. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
[TBL] [Abstract][Full Text] [Related]
5. Serum PICP as a bone formation marker in 89Sr and external beam radiotherapy of prostatic bony metastases.
Papatheofanis FJ
Br J Radiol; 1997 Jun; 70(834):594-8. PubMed ID: 9227252
[TBL] [Abstract][Full Text] [Related]
6. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
Brundage MD; Crook JM; Lukka H
Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
[TBL] [Abstract][Full Text] [Related]
7. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases.
Nair N
J Nucl Med; 1999 Feb; 40(2):256-61. PubMed ID: 10025832
[TBL] [Abstract][Full Text] [Related]
8. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
Storto G; Klain M; Paone G; Liuzzi R; Molino L; Marinelli A; Soricelli A; Pace L; Salvatore M
Bone; 2006 Jul; 39(1):35-41. PubMed ID: 16434248
[TBL] [Abstract][Full Text] [Related]
9. Variation in oncologic opinion regarding management of metastatic bone pain with systemic radionuclide therapy.
Papatheofanis FJ
J Nucl Med; 1999 Sep; 40(9):1420-3. PubMed ID: 10492359
[TBL] [Abstract][Full Text] [Related]
10. Disseminated intravascular coagulation in a patient with metastatic prostate cancer: fatal outcome following strontium-89 therapy.
Leong C; McKenzie MR; Coupland DB; Gascoyne RD
J Nucl Med; 1994 Oct; 35(10):1662-4. PubMed ID: 7931669
[TBL] [Abstract][Full Text] [Related]
11. [The efficacy of therapy using 89Sr-strontium chloride in 200 patients with bone metastases of a prostatic cancer].
Haesner M; Buchali K; Pink V; Lips H
Nuklearmedizin; 1992 Mar; 31(2):48-52. PubMed ID: 1373485
[TBL] [Abstract][Full Text] [Related]
12. Strontium 89 therapy for the palliation of pain due to osseous metastases.
Robinson RG; Preston DF; Schiefelbein M; Baxter KG
JAMA; 1995 Aug; 274(5):420-4. PubMed ID: 7542352
[TBL] [Abstract][Full Text] [Related]
13. Strontium-89 therapy for painful osseous metastatic prostate and breast cancer.
Hansen DV; Holmes ER; Catton G; Thorne DA; Chadwick DH; Schmutz DA
Am Fam Physician; 1993 Jun; 47(8):1795-800. PubMed ID: 7684554
[TBL] [Abstract][Full Text] [Related]
14. [Effectiveness of repeated systematic radiotherapy for generalized prostate cancer].
Kiselev EN; Korytova LI; Karelin MI
Vopr Onkol; 2005; 51(6):689-91. PubMed ID: 17037036
[TBL] [Abstract][Full Text] [Related]
15. Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy.
Malmberg I; Persson U; Ask A; Tennvall J; Abrahamsson PA
Urology; 1997 Nov; 50(5):747-53. PubMed ID: 9372886
[TBL] [Abstract][Full Text] [Related]
16. Strontium-89 for treatment of painful bone metastasis from prostate cancer.
Altman GB; Lee CA
Oncol Nurs Forum; 1996 Apr; 23(3):523-7. PubMed ID: 8801513
[TBL] [Abstract][Full Text] [Related]
17. Radionuclide therapy for painful bone metastases. An Italian multicentre observational study. Writing Committee of an Ad Hoc Study Group.
Piffanelli A; Dafermou A; Giganti M; Colamussi P; Pizzocaro C; Bestagno M;
Q J Nucl Med; 2001 Mar; 45(1):100-7. PubMed ID: 11456368
[TBL] [Abstract][Full Text] [Related]
18. [Strontium-89: a desirable therapeutic for bone metastases of prostate cancer].
Ma YB; Yan WL; Dai JC; Xu F; Yuan Q; Shi HH
Zhonghua Nan Ke Xue; 2008 Sep; 14(9):819-22. PubMed ID: 18998467
[TBL] [Abstract][Full Text] [Related]
19. [Radioactive substances (32P and 89Sr) in the treatment of pain in bone metastases].
Flamm J; Burkert S
Z Urol Nephrol; 1981 Nov; 74(11):801-6. PubMed ID: 6172913
[TBL] [Abstract][Full Text] [Related]
20. Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer.
Turner SL; Gruenewald S; Spry N; Gebski V;
Br J Cancer; 2001 Feb; 84(3):297-302. PubMed ID: 11161391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
